[go: up one dir, main page]

MX2009005993A - Tratamiento para ojo seco. - Google Patents

Tratamiento para ojo seco.

Info

Publication number
MX2009005993A
MX2009005993A MX2009005993A MX2009005993A MX2009005993A MX 2009005993 A MX2009005993 A MX 2009005993A MX 2009005993 A MX2009005993 A MX 2009005993A MX 2009005993 A MX2009005993 A MX 2009005993A MX 2009005993 A MX2009005993 A MX 2009005993A
Authority
MX
Mexico
Prior art keywords
treatment
composition
dry eye
eye
progestagen
Prior art date
Application number
MX2009005993A
Other languages
English (en)
Inventor
Charles G Connor
Charles Haine
Original Assignee
Southern College Of Optometry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern College Of Optometry filed Critical Southern College Of Optometry
Publication of MX2009005993A publication Critical patent/MX2009005993A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Eyeglasses (AREA)

Abstract

La presente invención se refiere a una composición y métodos para tratar condiciones del ojo (síndrome de ojo seco) usando una composición que tiene una cantidad terapéuticamente efectiva de un progestágeno y un portador farmacéuticamente aceptable, en donde la composición es aplicada a la parte palpebral del ojo y/o superficie ocular.
MX2009005993A 2006-12-05 2007-12-05 Tratamiento para ojo seco. MX2009005993A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/634,347 US20080132475A1 (en) 2006-12-05 2006-12-05 Treatment for dry eye
PCT/US2007/086515 WO2008070726A2 (en) 2006-12-05 2007-12-05 Treatment for dry eye

Publications (1)

Publication Number Publication Date
MX2009005993A true MX2009005993A (es) 2009-12-14

Family

ID=39476533

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009005993A MX2009005993A (es) 2006-12-05 2007-12-05 Tratamiento para ojo seco.
MX2009005994A MX2009005994A (es) 2006-12-05 2007-12-05 Tratamiento para ojo seco usando testosterona y progestageno.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009005994A MX2009005994A (es) 2006-12-05 2007-12-05 Tratamiento para ojo seco usando testosterona y progestageno.

Country Status (12)

Country Link
US (3) US20080132475A1 (es)
EP (2) EP2101785A4 (es)
JP (2) JP2010511729A (es)
KR (2) KR20090104813A (es)
CN (2) CN101636164A (es)
AU (1) AU2009202711A1 (es)
BR (2) BRPI0720172A2 (es)
CA (2) CA2671698A1 (es)
EA (2) EA200900662A1 (es)
IL (1) IL199094A0 (es)
MX (2) MX2009005993A (es)
WO (2) WO2008070726A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008289552B2 (en) * 2007-08-16 2014-10-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
WO2010016042A1 (en) * 2008-08-05 2010-02-11 University College Cork, National University Of Ireland, Cork Treatment of retinal degeneration
BR112013019257B1 (pt) * 2011-01-26 2019-09-03 Allergan Inc composição de androgênio para tratar uma condição oftálmica
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
HUE046963T2 (hu) 2012-07-27 2020-04-28 Glia Llc Készítmények és kezelés szembetegségekhez és rendellenességekhez
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN105188708B (zh) * 2013-03-15 2019-06-28 格利亚有限责任公司 颅部的药物递送
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
CN107106542B (zh) * 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
KR20170132319A (ko) * 2015-04-03 2017-12-01 산텐 세이야꾸 가부시키가이샤 난드롤론 또는 그 에스테르, 메테놀론 또는 그 에스테르를 유효 성분으로 하는 드라이아이 치료제
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3042213A1 (en) 2016-09-07 2018-03-15 Glia, Llc Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
WO2021097182A1 (en) * 2019-11-13 2021-05-20 Glia, Llc Testosterone compositions
WO2023107796A1 (en) * 2021-12-11 2023-06-15 The Regents Of The University Of California Ophthalmic formulations for macular degeneration

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS59184135A (ja) * 1983-04-04 1984-10-19 Teijin Ltd グリセリンピログルタミン酸エステル類を含有する医薬品組成物
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
DE3514724A1 (de) * 1985-04-24 1986-10-30 Albin F. Dr. 4200 Oberhausen Jereb Salbe zur verbeugung und behandlung von augen- und hauterkrankungen
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
USRE34578E (en) * 1990-05-07 1994-04-05 Lubkin; Virginia Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) * 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
WO1993020823A1 (en) * 1992-04-21 1993-10-28 The Schepens Eye Research Institute, Inc. Ocular androgen therapy in sjögren's syndrome
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
US5366739A (en) * 1992-08-06 1994-11-22 Deo Corporation Method of ophthalmic drug delivery
US5496811A (en) * 1992-08-28 1996-03-05 Pharmos Corp. Submicron emulsions as ocular drug delivery vehicles
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
CA2632790A1 (en) * 1996-07-22 1998-01-29 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
CA2281876A1 (en) * 1997-02-28 1998-09-03 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of testosterone
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
FR2774587B1 (fr) * 1998-02-09 2000-03-10 Oreal Utilisation d'une microdispersion de cire dans une composition cosmetique ou dermatologique
US6348210B1 (en) * 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
BR0011740A (pt) * 1999-06-11 2002-05-14 Watson Pharmaceuticals Inc Administração de esteróides androgênicos não-orais a mulheres
WO2001041806A1 (fr) * 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Compositions ophtalmiques
US6630175B1 (en) * 2000-06-29 2003-10-07 Johnson & Johnson Consumer Companies, Inc. Method of reducing eye irritation
CA2431566A1 (en) * 2000-12-11 2002-07-18 Testocreme, Llc Topical testosterone formulations and associated methods
US6659985B2 (en) * 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
AU2003290776A1 (en) * 2002-11-15 2004-06-15 Panaseca, Inc. Methods and compositions for alleviating dry eyes
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
WO2005041870A2 (en) * 2003-10-24 2005-05-12 Ader Enterprises, Inc. Composition and method for the treatment of eye disease
US20050202097A1 (en) * 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
US20060258698A1 (en) * 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen

Also Published As

Publication number Publication date
CN101636165A (zh) 2010-01-27
US20080132475A1 (en) 2008-06-05
KR20090104813A (ko) 2009-10-06
EA200900663A1 (ru) 2009-12-30
KR20090104814A (ko) 2009-10-06
CN101636164A (zh) 2010-01-27
IL199094A0 (en) 2010-03-28
EP2124958A4 (en) 2009-12-30
WO2008070728A2 (en) 2008-06-12
JP2010511729A (ja) 2010-04-15
EA200900662A1 (ru) 2009-12-30
US20140113889A1 (en) 2014-04-24
EP2101785A2 (en) 2009-09-23
MX2009005994A (es) 2009-12-14
WO2008070728A3 (en) 2008-08-07
EP2101785A4 (en) 2009-12-30
JP2010511730A (ja) 2010-04-15
EP2124958A2 (en) 2009-12-02
CA2671769A1 (en) 2008-06-12
BRPI0720172A2 (pt) 2014-01-07
WO2008070726A3 (en) 2008-08-21
CA2671698A1 (en) 2008-06-12
US20210008079A1 (en) 2021-01-14
AU2009202711A1 (en) 2009-07-23
BRPI0719918A2 (pt) 2014-03-04
WO2008070726A2 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
MX2009005993A (es) Tratamiento para ojo seco.
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
IL186598A0 (en) Composition and method for the treatment or prevention of glaucoma and ocular hypertension
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
CA2711696C (en) Therapeutic compositions for treatment of ocular inflammatory disorders
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
EA201001785A1 (ru) Модуляторы рецепторов сфингозин-1-фосфата
WO2005068421A8 (en) Prostaglandin nitrooxyderivatives
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
WO2008000513A3 (en) Peptide compounds for the treatment of hyperexcitability disorders and diseases associated with ion channel dysfunction
WO2007087151A3 (en) Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007095618A3 (en) Benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
WO2007108968A3 (en) Ophthalmic compositions for treating ocular hypertension
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
WO2007120817A3 (en) Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
NZ597866A (en) Therapeutic lactams
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2010022326A3 (en) Transdermal delivery of apomorphine using microneedles

Legal Events

Date Code Title Description
FA Abandonment or withdrawal